The sebetralstat Early Access Program (EAP) provides early access to the investigational medicinal product (IMP) sebetralstat to eligible and approved Type I or II Hereditary Angioedema (HAE) adolescent and adult post-trial and naïve patients for the on-demand treatment of angioedema attacks where the treating Physician determines they might benefit from this treatment.

Inclusion Criteria:

• At least 12 years of age.
• Able to provide written, informed consent or assent.
• Confirmed diagnosis of HAE Type I or II.

Exclusion Criteria:

• Confirmed diagnosis of HAE with nC1-INH or acquired angioedema.
• Confirmed pregnancy or breast-feeding.
• Any clinically significant medical condition or medical history that, in the opinion of the Treating Physician, would interfere with the patient's safety.
• Known hypersensitivity to sebetralstat or its excipients.
• Patient with a medical history or known to have severe hepatic impairment (Child Pugh C).
• Patients who require sustained use of strong cytochrome P450 3A4 inhibitors or inducers.